[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603267":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":27,"locations":19,"responsibleParty":34,"collaborators":19,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":19,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":19,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":59,"whyStopped":19,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":19},{"fullName":5,"class":6},"Clinica Universidad de Navarra, Universidad de Navarra","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation Phase","EXPERIMENTAL","Dose Escalation MR-guided TNT",[13],"Radiation: MR-Guided Irradiation",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":19},"RADIATION","MR-Guided Irradiation",[9],null,[21,25],{"name":22,"affiliation":23,"role":24},"Rafael Martínez-Monge, M.D.","Clínica Universidad de Navarra","PRINCIPAL_INVESTIGATOR",{"name":26,"affiliation":23,"role":24},"Luis Fuertes, M.D.",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Beatriz Ramos Aguirre, M.S.","CONTACT","+34 948255400","2772","ucicec@unav.es",{"type":35,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100603267","magnetic-resonance-imaging-mri-guided-rectal-cancer-preservation-program-100603267",false,"NCT07134296","Magnetic Resonance Imaging (MRI)-Guided Rectal Cancer Preservation Program","MRI-guided Rectal Cancer Preservation Program","Inclusion Criteria:\n\n* Patients aged 18 or older with primary Stage II (T3-4, N0) or Stage III (any T, N1-2) biopsy-proven rectal cancer\n* No prior radiation therapy to the target areas;\n* ECOG 0-2 with medical status not contraindicating treatment with radical intent including TNT and TME (if required) and with basal laboratory values as follows:\n\n  * Absolute neutrophil count (ANC) ≥ 1,000 cells\u002Fmm3\n  * Platelets ≥ 50,000 cells\u002Fmm3.\n  * Hemoglobin ≥ 8.0 g\u002Fdl.\n  * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\\u003C 4 x upper limit of normal.\n  * Total bilirubin \\\u003C 2 x upper normal mg\u002FdL.\n  * Alkaline phosphatase \\\u003C 4 x upper limit of normal.\n\nExclusion Criteria:\n\n* Patient unable to undergo an MRI examination","ALL","18 Years","80 Years",{"count":47,"type":48},32,"ESTIMATED","INTERVENTIONAL",[51],"NA","The goal of this clinical trial is to learn if the use of MRI-guided irradiation increases the rates of rectal preservation",[54],"Rectal Cancer",[56,57,58],"TNT","MRI-guided Irradiation","Rectal Preservation","NOT_YET_RECRUITING","2025-08-20",{"date":62,"type":63},"2025-08-21","ACTUAL",{"date":65,"type":48},"2025-10-01",{"date":67,"type":48},"2030-06-30",{"name":5,"class":6}]